The short version of receptor targets fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
The Gold Book, formally titled Compendium of Chemical Terminology, contains internationally accepted definitions for terms in chemistry. Work on the first edition was initiated by Victor Gold, thus spawning its informal name. The first edition was published in 1987 (ISBN 0-63201-765-1). The second (ISBN 0-86542-684-8), edited by A. D. McNaught and A. Wilkinson, was published in 1997. A slightly expanded version is also freely searchable online. Translations have also been published in French, Spanish and Polish.
=== Biological fluorescence === Chemical biologists often study the functions of biological macromolecules using fluorescence techniques. The advantage of fluorescence versus other techniques resides in its high sensitivity, non-invasiveness, safe detection, and ability to modulate the fluorescence signal. In recent years, the discovery of green fluorescent protein (GFP) by Roger Y. Tsien and others, hybrid systems and quantum dots have enabled assessing protein location and function more precisely. Three main types of fluorophores are used: small organic dyes, green fluorescent proteins, and quantum dots. Small organic dyes usually are less than 1 kDa, and have been modified to increase photostability and brightness, and reduce self-quenching. Quantum dots have very sharp wavelengths, high molar absorptivity and quantum yield. Both organic dyes and quantum dyes do not have the ability to recognize the protein of interest without the aid of antibodies, hence they must use immunolabeling. Fluorescent proteins are genetically encoded and can be fused to your protein of interest. Another genetic tagging technique is the tetracysteine biarsenical system, which requires modification of the targeted sequence that includes four cysteines, which binds membrane-permeable biarsenical molecules, the green and the red dyes "FlAsH" and "ReAsH", with picomolar affinity. Both fluorescent proteins and biarsenical tetracysteine can be expressed in live cells, but present major limitations in ectopic expression and might cause a loss of function.
Ever since the first discovery of Tyrannosaurus most scientists have agreed that it was an active predator, though like modern large predators it would readily scavenge or steal another predator's kill if it had the opportunity. Paleontologist Jack Horner has been a major proponent of the view that Tyrannosaurus was not a predator at all but instead was an obligate scavenger. He has put forward arguments in the popular literature to support the pure scavenger hypothesis:
Sources: en.wikipedia.org
=== Background === Mogo is a sentient and living planet. When it is desired, its affiliation with the Corps is shown with foliage arranged into a green band, marked with the standard Green Lantern Corps lantern symbol, circling Mogo's equator. In its early appearances, Mogo is not a social Green Lantern and its interactions with the rest of the DC universe are not well documented. It avoids announcing its presence, preferring to represent itself using pseudonymous holograms. In Mogo's first appearance, it is explained that the planet-sized Mogo's gravitational field would wreak havoc on any other planet it would try to "visit", hence Mogo "doesn't socialize". At the same time, Mogo has allowed alien races to live on its surface and has been willing to change its conditions to suit them. When Parallax, possessing Hal Jordan, destroys the power battery on Oa and kills the Guardians, Mogo loses contact with the Green Lantern energy that helped sustain him. Without energy, Mogo loses consciousness and drifts through Sector 1014 until he is discovered by a nomadic alien race, who strip Mogo of his natural resources and pollute his environment. Mogo's body reacts instinctively, creating constructs to hinder the aliens' efforts to exploit his resources. Mogo is finally rescued by Kyle Rayner, who uses his power ring to reawaken him. With the restoration of the Green Lantern Corps, Mogo has taken on the role of a training and recreation planet for his fellow Green Lanterns. Soranik Natu, Kyle Rayner, and other Lanterns have traveled to his sector to ask for his counsel.
Diallyl disulfide (DADS or 4,5-dithia-1,7-octadiene) is an organosulfur compound derived from garlic and a few other plants in the genus Allium. Along with diallyl trisulfide and diallyl tetrasulfide, it is one of the principal components of the distilled oil of garlic. It is a yellowish liquid which is insoluble in water and has a strong garlic odor. It is produced during the decomposition of allicin, which is released upon crushing garlic and other plants of the family Alliaceae. Diallyl disulfide has many of the health benefits of garlic, but it is also an allergen causing garlic allergy. Highly diluted, it is used as a flavoring in food. It decomposes in the human body into other compounds such as allyl methyl sulfide.
==== Resignation of Héctor Béjar ==== Almost immediately after his appointment as Foreign Minister, the media began reporting on Héctor Béjar's past. Béjar had been part of the National Liberation Army during the 1960s and had met Che Guevara according to his book "Peru 1965: Notes on a Guerrilla Experience." In a video published in November 2020, Béjar had said that 'terrorism began in the Navy' and that 'the Shining Path was trained by the CIA', leading to significant public backlash. Later, the Peruvian Navy put out a statement about wanting Béjar to retract, and claimed that Béjar's statement were an affront against those who fought against terrorism. Following that, Congress started an interpellation process against Béjar, which was seen by manyas a show trial that would be almost certainly followed by impeachment. However, Béjar resigned before the interpellations began. According to Béjar, Prime Minister Guido Bellido asked him to resign to prevent him from speaking before Congress, which he said was a way of censoring him. Béjar held the position of Foreign Minister for just 19 days. His replacement was the career diplomat Óscar Maúrtua. After his resignation, Béjar posted "I am free again!!!" on Facebook. Later, he would claim that this was the beginning of a soft coup against the Castillo's government. Béjar also claimed that there is a group in the Navy and the extreme right that does not want an independent foreign policy. He also claimed that his phrases were distorted and taken out of context.
Sources: en.wikipedia.org
The Syrian Jihad : Al-Qaeda, the Islamic state and the evolution of an insurgency Cecire, Michael (2016). "Same sides of different coins: contrasting militant activisms between Georgian fighters in Syria and Ukraine". Caucasus Survey. Brill Deutschland GmbH. 4 (3): 282–295. doi:10.1080/23761199.2016.1231382. ISSN 2376-1199. Vera Mironova. From Freedom Fighters to Jihadists: Human Resources of Non-State Armed Groups. — Oxford University Press, 2019-05-20. — 345 с. — ISBN 978-0-19-093978-6. The Syrian Jihad: Al-Qaeda, the Islamic State and the Evolution of an Insurgency Pokalova, Elena. Georgia, Terrorism, and Foreign Fighters Assessing Terrorism in the Caucasus and the Threat to the Homeland: Hearing In Russian
This model attempts to use these factors to predict the impact of lifestyle changes and genetics for the evolution of the MASLD pathology. Many researchers describe MASLD as a multisystem disease, as it impacts and is influenced by organs and regulatory pathways other than the liver. The accumulation of senescent cells in the liver is seen in persons with MASLD. In mice, liver senescent hepatocytes result in increased liver fat deposition. Treatment of MASLD mice with senolytic agents has been shown to reduce hepatic steatosis. Based on gene knockout studies in murine models, it has been suggested that, among many other pathogenic factors, TGF beta signals may be crucially involved in promoting the progression of MASH.
== Research == Trazodone may be effective in the treatment of sexual dysfunction, for instance female sexual dysfunction and erectile dysfunction. A 2003 systematic review and meta-analysis found some indication that trazodone may be useful in the treatment of erectile dysfunction. Besides trazodone alone, a combination of trazodone and bupropion (developmental code names and tentative brand names S1P-104, S1P-205, Lorexys, and Orexa) is under development for the treatment of erectile dysfunction and female sexual dysfunction. As of September 2021, it is in phase 2 clinical trials for these indications. It has been in this stage of clinical development since at least February 2015. Trazodone may be useful in the treatment of certain symptoms like sleep disturbances in alcohol withdrawal and recovery. However, reviews have recommended against use of trazodone for alcohol withdrawal due to inadequate evidence. Very limited evidence suggests that trazodone might be useful in the treatment of certain symptoms in cocaine use disorder. Trazodone has been reported to be effective in the treatment of sleep apnea. Cochrane reviews found that trazodone was not effective in the treatment of agitation in dementia. Another Cochrane review found that trazodone might be useful in the treatment of sleep disturbances in dementia. Further systematic reviews have found that trazodone may be effective for behavioral and psychological symptoms in dementias such as frontotemporal dementia and Alzheimer's disease.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.